Evaluation of the effectiveness of using two different
probiotics in helicobacter eradication treatment

YILDIRIM, murat; OZKAN, NAMIK; YÜRÜKER, SAIM SAVAS; BOSTAN, MUSTAFA SAMI; uğurlu, celil; Koca, Bülent; kiliç, erol

doi:10.14744/less.2021.03764

Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment

Bülent KOCA, (Gaziosmapaşa Üniversitesi, Genel Cerrahi Anabilim Dalı, Tokat, Türkiye)

Erol KILIÇ, (Mustafa Kemal Üniversitesi, Genel Cerrahi Anabilim Dalı, Tokat, Türkiye)

SAIM SAVAS YÜRÜKER, (Ondokuz Mayıs Üniversitesi, Genel Cerrahi Anabilim Dalı, Samsun, Türkiye)

Murat YILDIRIM, (Gaziosmapaşa Üniversitesi, Genel Cerrahi Anabilim Dalı, Tokat, Türkiye)

Mustafa Sami BOSTAN, (Gaziosmapaşa Üniversitesi, Genel Cerrahi Anabilim Dalı, Tokat, Türkiye)

Celil UĞURLU, (Gaziosmapaşa Üniversitesi, Genel Cerrahi Anabilim Dalı, Tokat, Türkiye)

Namık ÖZKAN (Gaziosmapaşa Üniversitesi, Genel Cerrahi Anabilim Dalı, Tokat, Türkiye)

Laparoscopic Endoscopic Surgical Science

8 0

Yıl: 2021 Cilt: 28 Sayı: 4 Sayfa Aralığı: 176 - 181 Metin Dili: İngilizce DOI: 10.14744/less.2021.03764 İndeks Tarihi: 15-06-2022

Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment

Öz:

Introduction: We aimed to evaluate the effects of the addition of probiotics containing Lactobacillus acidophilus + Bifidobacterium animalis Subsp lactis to the classic triple treatment protocol (lansoprozole + amoxycillin + clarithromycin) on the success of Helicobacter pylori eradication and antibiotic side effects. Materials and Methods: Standard therapy (lansoprozole + amoxycillin + clarithromycin), and probiotics containing in addition to standard therapy were determined. Patients in both groups were treated for 14 days. The prebiotic, containing two different strains, was in capsule form and used twice a day. We demonstrated the helicobacter eradication status by looking at the helicobacter antigen from the stool. Statistical analyzes between the two groups were made using the pearson Chi-square test. P<0.05 was accepted as the significance level. Results: The rate of discontinuing treatment due to side effects was 15.3% in group 1, this rate was 4.5% in group 2. When double probiotics were added to the treatment, it was observed that there was a decrease of 11.2% in serious side effects (p<0.001). After the completion of the treatments. It was observed that helicobacter eradication was achieved in 152 out of 222 patients (68%) in group 1 and in 214 (89%) of 240 patients in group 2. When double probiotics were added to the treatment, it was observed that the success of eradication increased by 21% (p<0.001). Conclusion: Combined use of probiotic increases helicobacter eradication in addition to reducing the side effects of antibiotics due to H. pylori.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420–9.
2. Sjökvist Ottsjö L, Jeverstam F, Yrlid L, Wenzel AU, Walduck AK, Raghavan S. Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization. Immunology 2017;150:172–83.
3. Bagheri N, Azadegan-Dehkordi F, Rafieian-Kopaei M, Rahimian G, Asadi-Samani M, Shirzad H. Clinical relevance of Helicobacter pylori virulence factors in Iranian patients with gastrointestinal diseases. Microb Pathog 2016;100:154–62.
4. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420–9.
5. O’Connor A, O’Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2017;14:230–40.
6. Malfertheiner P, Megraud F, O’Morain AC. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6–30.
7. Asgari B, Kermanian F, Derakhshan N, Asna-Ashari M, Sadat ZRN, Yaslianifard S. Honey-derived Lactobacillus rhamnosus alleviates Helicobacter pylori-induced gastro-intestinal infection and gastric inflammation in C57BL/6 mice: an immuno- histologic study. Arq Gastroenterol 2018;55:279–82.
8. Talebi Bezmin Abadi A. Probiotics as Anti-Helicobacterpylori Agent: State of the Art. Anti Infect Agents 2017;15:63–8.
9. Evans JD, Lopez DL. Bacterial probiotics induce an immune response in the honey bee (Hymenoptera: Apidae). J Econ Entomol 2004;97:752–6.
10. Mousavi S, Dehkordi FS, Rahimi E. Virulence factors and antibiotic resistance of Helicobacter pylori isolated from raw milk and unpasteurized dairy products in Iran. J Venom Anim ToxinsIncl Trop Dis 2014;20:51.
11. Yahaghi E, Khamesipour F, Mashayekhi F, Safarpoor Dehkordi F, Sakhaei MH, Masoudimanesh M, et al. Helicobacter pylori in vegetables and salads: genotyping and antimicrobial resistance properties. Biomed Res Int 2014;2014:757941.
12. Tuccori M, Lapi F, Testi A, Ruggiero E, Moretti U, Vannacci A, et al. Drug-induced taste and smell alterations: a case/ non-case evaluation of an italian database of spontaneous adverse drug reaction reporting. Drug Saf 2011;34:849–59.
13. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006;101:1921–30.
14. Nguyen TV, Bengtsson C, Nguyen GK, Granström M. Evaluation of a novel monoclonal-based antigen-in-stool enzyme immunoassay (Premier Platinum HpSA PLUS) for diagnosis of Helicobacter pylori infection in Vietnamese children. Helicobacter 2008;13:269–73.
15. Jarosz M, Rychlik E, Siuba M, Respondek W, Ryzko-Skiba M, Sajór I, et al. Dietary and socio-economic factors in relation to Helicobacter pylori re-infection. World J Gastroenterol 2009;15:1119–25.
16. Peek RM. Helicobacter pylori infection and disease: from humans to animal models. Dis Model Mech 2008;1:50–5.
17. Haesebrouck F, Pasmans F, Flahou B, Chiers K, Baele M, Meyns T, et al. Gastric helicobacters in domestic animals and nonhuman primates and their significance for human health. Clin Microbiol Rev 2009;22:202–23.
18. Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study. Turk J Gastroenterol 2018;29:549–54.
19. Elitsur Y, Lawrence Z, Rüssmann H, Koletzko S. Primary clarithromycin resistance to Helicobacter pylori and therapy failure in children: the experience inWest Virginia. J Pediatr Gastroenterol Nutr 2006;42:327–8.
20. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, et al. Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period. Surg Endosc 2012;26:72–8.
21. Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006;55:1711–6.
22. Göral V, Yıldız Zeyrek F, Gül K. Helicobacter pylori infeksiyonunda antibiyotik direnci. T Klin Gastroenterohepatol 2000;11:87–92.
23. McFarland LV, Malfertheiner P, Huang Y, Wang L. Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World J Meta-Anal 2015;3:97–117.
24. McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Euro J Gastroenterol 2016;4:546–61.
25. Joint FAO/WHO Working Group. Report on drafting guidelines for the evaluation of probiotics in food. London Ontario, Canada, April 30 and May 1, 2002. Available at: https://www. who.int/foodsafety/fs_management/en/probiotic_guidelines. pdf. Accessed Oct 20, 2021.
26. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010;5:e9836.
27. Salazar N, Ruas-Madiedo P, Kolida S, Collins M, Rastall R, Gibson G, et al. Exopolysaccharides produced by Bifidobacterium longum IPLA E44 and Bifidobacterium animalis subsp. lactis IPLA R1 modify the composition and metabolic activity of human faecal microbiota in pH-controlled batch cultures. Int J Food Microbiol 2009;135:260–7.
28. Labigne A, Cussac V, Courcoux P. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity. J Bacteriol 1991;173:1920–31,
29. Josenhans C, Suerbaum S. Helicobacter motility and chemotaxis. In: Achtman M, Saeubaum S, editors. Helicobacter pylori: molecular and cellular biology. Norfolk: Horizon Scientific Press; 2001. p. 171–84.
30. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;295:683–6.
31. Telford JL, Ghiara P, Dell’Orco M, Comanducci M, Burroni D, Bugnoli M, et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994;179:1653–8.
32. World Gastroenterology Organisation. World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol 2011;45:383–8.
33. Chen YH, Tsai WH, Wu HY, Chen CY, Yeh WL, Chen YH, et al. Probiotic Lactobacillus spp. act Against Helicobacter pyloriinduced Inflammation. J Clin Med 2019;8:90.
34. Asgari B, Kermanian F, Hedayat Yaghoobi M, Vaezi A, Soleimanifar F, Yaslianifard S. The anti-helicobacter pylori effects of lactobacillus acidophilus, L. plantarum, and L. rhamnosus in Stomach Tissue of C57BL/6 Mice. Visc Med 2020;36:137–43.
35. Chenoll E, Casinos B, Bataller E, Astals P, Echevarría J, Iglesias JR, et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol 2011;77:1335–43.
36. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6–30.
37. Lü M, Yu S, Deng J, Yan Q, Yang C, Xia G, et al. Efficacy of probiotic supplementation therapy for helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One 2016;11:e0163743.
38. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacteriumcontaining probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25– 32.

APA	Koca B, kiliç e, YÜRÜKER S, YILDIRIM m, BOSTAN M, uğurlu c, OZKAN N (2021). Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. , 176 - 181. 10.14744/less.2021.03764
Chicago	Koca Bülent,kiliç erol,YÜRÜKER SAIM SAVAS,YILDIRIM murat,BOSTAN MUSTAFA SAMI,uğurlu celil,OZKAN NAMIK Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. (2021): 176 - 181. 10.14744/less.2021.03764
MLA	Koca Bülent,kiliç erol,YÜRÜKER SAIM SAVAS,YILDIRIM murat,BOSTAN MUSTAFA SAMI,uğurlu celil,OZKAN NAMIK Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. , 2021, ss.176 - 181. 10.14744/less.2021.03764
AMA	Koca B,kiliç e,YÜRÜKER S,YILDIRIM m,BOSTAN M,uğurlu c,OZKAN N Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. . 2021; 176 - 181. 10.14744/less.2021.03764
Vancouver	Koca B,kiliç e,YÜRÜKER S,YILDIRIM m,BOSTAN M,uğurlu c,OZKAN N Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. . 2021; 176 - 181. 10.14744/less.2021.03764
IEEE	Koca B,kiliç e,YÜRÜKER S,YILDIRIM m,BOSTAN M,uğurlu c,OZKAN N "Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment." , ss.176 - 181, 2021. 10.14744/less.2021.03764
ISNAD	Koca, Bülent vd. "Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment". (2021), 176-181. https://doi.org/10.14744/less.2021.03764

APA	Koca B, kiliç e, YÜRÜKER S, YILDIRIM m, BOSTAN M, uğurlu c, OZKAN N (2021). Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. Laparoscopic Endoscopic Surgical Science, 28(4), 176 - 181. 10.14744/less.2021.03764
Chicago	Koca Bülent,kiliç erol,YÜRÜKER SAIM SAVAS,YILDIRIM murat,BOSTAN MUSTAFA SAMI,uğurlu celil,OZKAN NAMIK Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. Laparoscopic Endoscopic Surgical Science 28, no.4 (2021): 176 - 181. 10.14744/less.2021.03764
MLA	Koca Bülent,kiliç erol,YÜRÜKER SAIM SAVAS,YILDIRIM murat,BOSTAN MUSTAFA SAMI,uğurlu celil,OZKAN NAMIK Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. Laparoscopic Endoscopic Surgical Science, vol.28, no.4, 2021, ss.176 - 181. 10.14744/less.2021.03764
AMA	Koca B,kiliç e,YÜRÜKER S,YILDIRIM m,BOSTAN M,uğurlu c,OZKAN N Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. Laparoscopic Endoscopic Surgical Science. 2021; 28(4): 176 - 181. 10.14744/less.2021.03764
Vancouver	Koca B,kiliç e,YÜRÜKER S,YILDIRIM m,BOSTAN M,uğurlu c,OZKAN N Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment. Laparoscopic Endoscopic Surgical Science. 2021; 28(4): 176 - 181. 10.14744/less.2021.03764
IEEE	Koca B,kiliç e,YÜRÜKER S,YILDIRIM m,BOSTAN M,uğurlu c,OZKAN N "Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment." Laparoscopic Endoscopic Surgical Science, 28, ss.176 - 181, 2021. 10.14744/less.2021.03764
ISNAD	Koca, Bülent vd. "Evaluation of the effectiveness of using two different probiotics in helicobacter eradication treatment". Laparoscopic Endoscopic Surgical Science 28/4 (2021), 176-181. https://doi.org/10.14744/less.2021.03764